(ISRG) Intuitive Surgical - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US46120E6023
Stock: Surgical Systems, Endoluminal Systems, Instruments, Support, Digital
Total Rating 58
Risk 95
Buy Signal 0.08
| Risk 5d forecast | |
|---|---|
| Volatility | 29.7% |
| Relative Tail Risk | -11.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.07 |
| Alpha | -24.41 |
| Character TTM | |
|---|---|
| Beta | 0.945 |
| Beta Downside | 0.425 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.63% |
| CAGR/Max DD | 0.93 |
EPS (Earnings per Share)
Revenue
Description: ISRG Intuitive Surgical March 04, 2026
Intuitive Surgical, Inc. (ISRG) develops and markets robotic surgical systems and instruments. Its primary product, the da Vinci Surgical System, facilitates minimally invasive surgeries. The company also offers the Ion endoluminal system for diagnostic lung biopsies. The medical device sector is characterized by high research and development costs and long product development cycles.
ISRGs business model includes selling surgical systems, instruments, and providing ongoing services. These services encompass installation, maintenance, technical support, and digital performance insights. The company utilizes a direct sales force for its products. Further research on platforms like ValueRay can provide deeper insights into ISRGs financial performance and market position.
Headlines to watch out for
- da Vinci system sales drive revenue growth
- Instrument and accessory sales boost recurring income
- Ion system adoption expands diagnostic market share
- Regulatory approvals impact new product launches
- Hospital capital expenditure cycles affect system sales
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 2.86b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 5.15 > 1.0 |
| NWC/Revenue: 77.23% < 20% (prev 64.24%; Δ 12.99% < -1%) |
| CFO/TA 0.15 > 3% & CFO 3.03b > Net Income 2.86b |
| Net Debt (-3.07b) to EBITDA (3.62b): -0.85 < 3 |
| Current Ratio: 4.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (360.4m) vs 12m ago -0.96% < -2% |
| Gross Margin: 66.00% > 18% (prev 0.67%; Δ 6532 % > 0.5%) |
| Asset Turnover: 51.00% > 50% (prev 44.34%; Δ 6.66% > 0%) |
| Interest Coverage Ratio: 32.58 > 6 (EBITDA TTM 3.62b / Interest Expense TTM 90.4m) |
Altman Z'' 7.34
| A: 0.38 (Total Current Assets 9.78b - Total Current Liabilities 2.01b) / Total Assets 20.63b |
| B: 0.34 (Retained Earnings 7.01b / Total Assets 20.63b) |
| C: 0.15 (EBIT TTM 2.95b / Avg Total Assets 19.73b) |
| D: 2.62 (Book Value of Equity 7.06b / Total Liabilities 2.69b) |
| Altman-Z'' Score: 7.34 = AAA |
Beneish M -3.03
| DSRI: 1.00 (Receivables 1.63b/1.36b, Revenue 10.06b/8.35b) |
| GMI: 1.02 (GM 66.00% / 67.46%) |
| AQI: 0.72 (AQ_t 0.27 / AQ_t-1 0.37) |
| SGI: 1.21 (Revenue 10.06b / 8.35b) |
| TATA: -0.01 (NI 2.86b - CFO 3.03b) / TA 20.63b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of ISRG shares?
As of March 11, 2026, the stock is trading at USD 485.85 with a total of 1,458,147 shares traded.
Over the past week, the price has changed by -2.33%, over one month by -1.88%, over three months by -12.60% and over the past year by +0.67%.
Over the past week, the price has changed by -2.33%, over one month by -1.88%, over three months by -12.60% and over the past year by +0.67%.
Is ISRG a buy, sell or hold?
Intuitive Surgical has received a consensus analysts rating of 4.03.
Therefore, it is recommended to buy ISRG.
- StrongBuy: 14
- Buy: 8
- Hold: 10
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the ISRG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 609.8 | 25.5% |
| Analysts Target Price | 609.8 | 25.5% |
ISRG Fundamental Data Overview March 11, 2026
P/E Trailing = 62.8739
P/E Forward = 49.2611
P/S = 17.4151
P/B = 9.7661
P/EG = 2.5367
Revenue TTM = 10.06b USD
EBIT TTM = 2.95b USD
EBITDA TTM = 3.62b USD
Long Term Debt = 263.8m USD (estimated: total debt 302.8m - short term 39.0m)
Short Term Debt = 39.0m USD (from shortTermDebt, last quarter)
Debt = 302.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.07b USD (from netDebt column, last quarter)
Enterprise Value = 169.65b USD (175.28b + Debt 302.8m - CCE 5.93b)
Interest Coverage Ratio = 32.58 (Ebit TTM 2.95b / Interest Expense TTM 90.4m)
EV/FCF = 68.11x (Enterprise Value 169.65b / FCF TTM 2.49b)
FCF Yield = 1.47% (FCF TTM 2.49b / Enterprise Value 169.65b)
FCF Margin = 24.75% (FCF TTM 2.49b / Revenue TTM 10.06b)
Net Margin = 28.38% (Net Income TTM 2.86b / Revenue TTM 10.06b)
Gross Margin = 66.00% ((Revenue TTM 10.06b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 66.44% (prev 66.36%)
Tobins Q-Ratio = 8.22 (Enterprise Value 169.65b / Total Assets 20.63b)
Interest Expense / Debt = 29.85% (Interest Expense 90.4m / Debt 302.8m)
Taxrate = 16.34% (156.1m / 955.6m)
NOPAT = 2.46b (EBIT 2.95b * (1 - 16.34%))
Current Ratio = 4.87 (Total Current Assets 9.78b / Total Current Liabilities 2.01b)
Debt / Equity = 0.02 (Debt 302.8m / totalStockholderEquity, last quarter 17.82b)
Debt / EBITDA = -0.85 (Net Debt -3.07b / EBITDA 3.62b)
Debt / FCF = -1.23 (Net Debt -3.07b / FCF TTM 2.49b)
Total Stockholder Equity = 17.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.47% (Net Income 2.86b / Total Assets 20.63b)
RoE = 16.39% (Net Income TTM 2.86b / Total Stockholder Equity 17.43b)
RoCE = 16.65% (EBIT 2.95b / Capital Employed (Equity 17.43b + L.T.Debt 263.8m))
RoIC = 14.14% (NOPAT 2.46b / Invested Capital 17.43b)
WACC = 9.43% (E(175.28b)/V(175.58b) * Re(9.40%) + D(302.8m)/V(175.58b) * Rd(29.85%) * (1-Tc(0.16)))
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.31%
[DCF] Terminal Value 73.68% ; FCFF base≈2.02b ; Y1≈2.09b ; Y5≈2.39b
[DCF] Fair Price = 100.4 (EV 32.59b - Net Debt -3.07b = Equity 35.65b / Shares 355.1m; r=9.43% [WACC]; 5y FCF grow 4.02% → 2.90% )
EPS Correlation: 97.03 | EPS CAGR: 23.98% | SUE: 2.02 | # QB: 3
Revenue Correlation: 98.06 | Revenue CAGR: 19.11% | SUE: 2.17 | # QB: 6
EPS next Quarter (2026-06-30): EPS=2.48 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=+5 | Analysts=27
EPS current Year (2026-12-31): EPS=10.02 | Chg7d=+0.005 | Chg30d=-0.000 | Revisions Net=+4 | Growth EPS=+12.2% | Growth Revenue=+14.6%
EPS next Year (2027-12-31): EPS=11.44 | Chg7d=+0.006 | Chg30d=+0.004 | Revisions Net=+5 | Growth EPS=+14.2% | Growth Revenue=+13.6%
[Analyst] Revisions Ratio: +1.00 (5 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.8% (Discount Rate 9.4% - Earnings Yield 1.6%)
[Growth] Growth Spread = +6.8% (Analyst 14.6% - Implied 7.8%)
P/E Forward = 49.2611
P/S = 17.4151
P/B = 9.7661
P/EG = 2.5367
Revenue TTM = 10.06b USD
EBIT TTM = 2.95b USD
EBITDA TTM = 3.62b USD
Long Term Debt = 263.8m USD (estimated: total debt 302.8m - short term 39.0m)
Short Term Debt = 39.0m USD (from shortTermDebt, last quarter)
Debt = 302.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.07b USD (from netDebt column, last quarter)
Enterprise Value = 169.65b USD (175.28b + Debt 302.8m - CCE 5.93b)
Interest Coverage Ratio = 32.58 (Ebit TTM 2.95b / Interest Expense TTM 90.4m)
EV/FCF = 68.11x (Enterprise Value 169.65b / FCF TTM 2.49b)
FCF Yield = 1.47% (FCF TTM 2.49b / Enterprise Value 169.65b)
FCF Margin = 24.75% (FCF TTM 2.49b / Revenue TTM 10.06b)
Net Margin = 28.38% (Net Income TTM 2.86b / Revenue TTM 10.06b)
Gross Margin = 66.00% ((Revenue TTM 10.06b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 66.44% (prev 66.36%)
Tobins Q-Ratio = 8.22 (Enterprise Value 169.65b / Total Assets 20.63b)
Interest Expense / Debt = 29.85% (Interest Expense 90.4m / Debt 302.8m)
Taxrate = 16.34% (156.1m / 955.6m)
NOPAT = 2.46b (EBIT 2.95b * (1 - 16.34%))
Current Ratio = 4.87 (Total Current Assets 9.78b / Total Current Liabilities 2.01b)
Debt / Equity = 0.02 (Debt 302.8m / totalStockholderEquity, last quarter 17.82b)
Debt / EBITDA = -0.85 (Net Debt -3.07b / EBITDA 3.62b)
Debt / FCF = -1.23 (Net Debt -3.07b / FCF TTM 2.49b)
Total Stockholder Equity = 17.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.47% (Net Income 2.86b / Total Assets 20.63b)
RoE = 16.39% (Net Income TTM 2.86b / Total Stockholder Equity 17.43b)
RoCE = 16.65% (EBIT 2.95b / Capital Employed (Equity 17.43b + L.T.Debt 263.8m))
RoIC = 14.14% (NOPAT 2.46b / Invested Capital 17.43b)
WACC = 9.43% (E(175.28b)/V(175.58b) * Re(9.40%) + D(302.8m)/V(175.58b) * Rd(29.85%) * (1-Tc(0.16)))
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.31%
[DCF] Terminal Value 73.68% ; FCFF base≈2.02b ; Y1≈2.09b ; Y5≈2.39b
[DCF] Fair Price = 100.4 (EV 32.59b - Net Debt -3.07b = Equity 35.65b / Shares 355.1m; r=9.43% [WACC]; 5y FCF grow 4.02% → 2.90% )
EPS Correlation: 97.03 | EPS CAGR: 23.98% | SUE: 2.02 | # QB: 3
Revenue Correlation: 98.06 | Revenue CAGR: 19.11% | SUE: 2.17 | # QB: 6
EPS next Quarter (2026-06-30): EPS=2.48 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=+5 | Analysts=27
EPS current Year (2026-12-31): EPS=10.02 | Chg7d=+0.005 | Chg30d=-0.000 | Revisions Net=+4 | Growth EPS=+12.2% | Growth Revenue=+14.6%
EPS next Year (2027-12-31): EPS=11.44 | Chg7d=+0.006 | Chg30d=+0.004 | Revisions Net=+5 | Growth EPS=+14.2% | Growth Revenue=+13.6%
[Analyst] Revisions Ratio: +1.00 (5 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.8% (Discount Rate 9.4% - Earnings Yield 1.6%)
[Growth] Growth Spread = +6.8% (Analyst 14.6% - Implied 7.8%)